Cargando…
Structural Isomerism and Enhanced Lipophilicity of Pyrithione Ligands of Organoruthenium(II) Complexes Increase Inhibition on AChE and BuChE
The increasing number of Alzheimer’s disease (AD) cases requires the development of new improved drug candidates, possessing the ability of more efficient treatment as well as less unwanted side effects. Cholinesterase enzymes are highly associated with the development of AD and thus represent impor...
Autores principales: | Kladnik, Jerneja, Ristovski, Samuel, Kljun, Jakob, Defant, Andrea, Mancini, Ines, Sepčić, Kristina, Turel, Iztok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460603/ https://www.ncbi.nlm.nih.gov/pubmed/32781544 http://dx.doi.org/10.3390/ijms21165628 |
Ejemplares similares
-
Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells
por: Kladnik, Jerneja, et al.
Publicado: (2021) -
Novel Organoruthenium(II) Complex C1 Selectively Inhibits Butyrylcholinesterase without Side Effects on Neuromuscular Transmission
por: Trobec, Tomaž, et al.
Publicado: (2023) -
Fine Tuning of Cholinesterase and Glutathione-S-Transferase Activities by Organoruthenium(II) Complexes
por: Trobec, Tomaž, et al.
Publicado: (2021) -
Comparison of Solution Chemical Properties and Biological Activity of Ruthenium Complexes of Selected β-Diketone, 8-Hydroxyquinoline and Pyrithione Ligands
por: Pivarcsik, Tamás, et al.
Publicado: (2021) -
Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS
por: Marković, Katarina, et al.
Publicado: (2020)